Aliso Viejo, California, March 23, 2021 – Visionary Ventures today announced the closing of Visionary Venture Fund II with $114MM in committed capital. The Fund, which was strongly supported by existing and new investors, continues the firm’s strategy of partnering with Ophthalmology and Optometry Key Opinion Leader (KOL) limited partners to invest in ophthalmic pharmaceuticals and medical devices. Fund II enjoys investment and input from over 80 KOL experts spanning the front and back of the eye.
Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a broad range of ophthalmic indications, including wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma.